212 related articles for article (PubMed ID: 37178730)
41. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
Frølunde AS; Wiis MAK; Ben Abdallah H; Elsgaard S; Danielsen AK; Deleuran M; Vestergaard C
Dermatology; 2022; 238(5):950-960. PubMed ID: 35417906
[TBL] [Abstract][Full Text] [Related]
42. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
43. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
44. Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial.
Jang JH; Jun P; Park G; Kwon O; Choi Y; Lim HS; Moon BC; Kim K
Medicine (Baltimore); 2022 Nov; 101(46):e31470. PubMed ID: 36401407
[TBL] [Abstract][Full Text] [Related]
45. Role of Pregabalin in Management of Pruritus: A Literature Review.
Foroutan N; Nikvarz N
J Pharm Pharm Sci; 2016; 19(4):465-474. PubMed ID: 28057164
[TBL] [Abstract][Full Text] [Related]
46. Non-corticosteroid adherence and itch severity influence perception of itch in atopic dermatitis.
Takeuchi S; Oba J; Esaki H; Furue M
J Dermatol; 2018 Feb; 45(2):158-164. PubMed ID: 29168215
[TBL] [Abstract][Full Text] [Related]
47. Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.
Gründel S; Pereira MP; Storck M; Osada N; Schneider G; Ständer S; Zeidler C
Acta Derm Venereol; 2020 Sep; 100(16):adv00269. PubMed ID: 32556359
[TBL] [Abstract][Full Text] [Related]
48. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
[TBL] [Abstract][Full Text] [Related]
49. [Treatment of chronic itch in systemic disease. Current standards].
Mettang T; Ständer S; Kremer AE
Internist (Berl); 2015 Dec; 56(12):1369-78. PubMed ID: 26585238
[TBL] [Abstract][Full Text] [Related]
50. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
Phan NQ; Bernhard JD; Luger TA; Ständer S
J Am Acad Dermatol; 2010 Oct; 63(4):680-8. PubMed ID: 20462660
[TBL] [Abstract][Full Text] [Related]
51. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions.
van Laarhoven AIM; van der Sman-Mauriks IM; Donders ART; Pronk MC; van de Kerkhof PCM; Evers AWM
J Invest Dermatol; 2015 May; 135(5):1234-1243. PubMed ID: 25609025
[TBL] [Abstract][Full Text] [Related]
52. Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes.
Zeidler C; Pereira MP; Ständer S
Front Med (Lausanne); 2021; 8():649332. PubMed ID: 34268319
[TBL] [Abstract][Full Text] [Related]
53. A review of the current management and burden of prurigo nodularis in the United States.
Chisolm SS
Am J Manag Care; 2023 May; 29(5 Suppl):S63-S72. PubMed ID: 37146288
[TBL] [Abstract][Full Text] [Related]
54. How to define chronic prurigo?
Pereira MP; Ständer S
Exp Dermatol; 2019 Dec; 28(12):1455-1460. PubMed ID: 31102542
[TBL] [Abstract][Full Text] [Related]
55. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
56. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
Pezzolo E; Gambardella A; Guanti M; Bianchelli T; Bertoldi A; Giacchetti A; Donini M; Argenziano G; Naldi L
J Am Acad Dermatol; 2023 Aug; 89(2):430-432. PubMed ID: 37150301
[No Abstract] [Full Text] [Related]
57. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching.
Shao Y; Zhu Y; Xiao Z; Shen Y; Dai B; Tang H; Wang D
Exp Dermatol; 2023 Jan; 32(1):30-40. PubMed ID: 36134503
[TBL] [Abstract][Full Text] [Related]
58. [Antipruritic effects of pimecrolimus and tacrolimus].
Ständer S; Luger TA
Hautarzt; 2003 May; 54(5):413-7. PubMed ID: 12719860
[TBL] [Abstract][Full Text] [Related]
59. Itch and Janus Kinase Inhibitors.
Han Y; Woo YR; Cho SH; Lee JD; Kim HS
Acta Derm Venereol; 2023 Feb; 103():adv00869. PubMed ID: 36789757
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
